Clinical trials: Hypogonadism
Hypogonadism, Male
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
This is a 52-week open label single arm study + 24-Month long-term safety extension to investigate the effects of XYOSTED, as testosterone replacement therapy, on adolescent males with either primary or secondary hypogonadism.
- Trial name
- NCT06689085
- Testing
- Testosterone enanthate
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Halozyme Therapeutics
Hypogonadism, Male
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
The purpose of this six-month treatment study is to assess feasibility of a lower starting dose of SOV2012-F1 (daily dose of 400 mg [200 mg with breakfast meal and 200mg with dinner meal]) to titrate individual doses to further…
- Trial name
- NCT04467697
- Testing
- SOV2012-F1
- Where
- 19 sites in United States
- Volunteers
- 155 people
- Sponsor
- Marius Pharmaceuticals
Hypogonadism, Hypogonadism, Male
Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride
The combination of testosterone and dutasteride is intended for use in hypogonadal men. This study will evaluate the bioavailability and pharmacokinetics of various doses of testosterone administered with and without dutasteride
- Trial name
- NCT00400335
- Testing
- Nanomilled testosterone, commercially available dutasteride, Nanomilled dutasteride
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypogonadism
A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants
This study will evaluate the effect of a once daily Androderm® dose on Blood Pressure (BP) in adult hypogonadal men as measured by 24-hour ABPM.
- Trial name
- NCT04320745
- Testing
- Androderm®
- Where
- 41 sites in United States
- Volunteers
- 168 people
- Sponsor
- Allergan
Hypogonadism
Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men
The study will evaluate the pharmacokinetics of testosterone transdermal systems at steady-state in hypogonadal men.
- Trial name
- NCT01104246
- Testing
- Testerone Transdermal System
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Watson Pharmaceuticals
Secondary Hypogonadism
Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism
The purpose of ZA-301 is to determine the effects of Androxal on morning testosterone and reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T<300 ng/dL) and normal sperm…
- Trial name
- NCT01532414
- Testing
- Androxal
- Where
- 23 sites in United States
- Volunteers
- 151 people
- Sponsor
- Repros Therapeutics Inc.
Hypogonadism, Male
Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes
To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid…
- Trial name
- NCT03973840
- Testing
- Testosterone Undecanoate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Clarus Therapeutics, Inc.
Hypogonadism
A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
Hypogonadism is an endocrine disorder characterized by absent or deficient testosterone levels along with signs and symptoms of androgen deficiency, including delayed development or regression of sexual characteristics, impaired…
- Trial name
- NCT04274894
- Testing
- AndroGel 1.62%
- Where
- 45 sites in United States
- Volunteers
- 246 people
- Sponsor
- AbbVie
Secondary Hypogonadism
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
This is a Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with the 12.5…
- Trial name
- NCT01993212
- Testing
- Androxal 12.5 mg or 25 mg, AndroGel 1.62%
- Where
- 8 sites in United States
- Volunteers
- 120 people
- Sponsor
- Repros Therapeutics Inc.
Male Hypogonadism, Sexual Dysfunction
D-chiroinositol Administration in Hypogonadal Males
D-chiroinositol (DCI), is known as second messenger of insulin pathway, but recently several works have reported the influence of DCI on steroidogenesis.
- Trial name
- NCT04708249
- Testing
- D-chiroinositol
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Lo.Li.Pharma s.r.l
Adult Male Hypogonadism
A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males
This is a phase 3, open-label, non-randomized, clinical trial to evaluate the efficacy and safety of FE 999303 (Testosterone gel) in adult hypogonadal males.
- Trial name
- NCT02149264
- Testing
- Testosterone gel (FE 999303)
- Where
- 22 sites in United States
- Volunteers
- 160 people
- Sponsor
- Ferring Pharmaceuticals
Hypogonadism, Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy
The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 4 weeks in the treatment of hypogonadal men with chronic obstructive…
- Trial name
- NCT01061970
- Testing
- Fispemifene
- Volunteers
- 15 people
- Sponsor
- QuatRx Pharmaceuticals Company
Male, Hypogonadism
Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice
This is an observational study with a drug called Nebido, a new testosterone replacement therapy, which is available for the treatment of male hypogonadism.
- Trial name
- IPASS Nebido (NCT00410306)
- Testing
- Testosterone Undecanoate (Nebido, BAY86-5037)
- Where
- 33 sites in Australia, Austria and 31 more
- Volunteers
- 1,493 people
- Sponsor
- Bayer
Secondary Hypogonadism
Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism
The purpose of ZA-302 is to determine the effects of Androxal on morning testosterone and reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T<300 ng/dL) and normal sperm…
- Trial name
- NCT01739595
- Testing
- enclomiphene citrate
- Where
- 13 sites in United States
- Volunteers
- 181 people
- Sponsor
- Repros Therapeutics Inc.
Male Hypogonadism
Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism
The goal of this Phase 3 clinical trial is to evaluate the safety, efficacy, and usability of a weekly subcutaneous testosterone cypionate auto-injector in adult males with hypogonadism.
- Trial name
- NCT07898072
- Testing
- Testosterone Cypionate 75 mg, Testosterone cypionate 50 mg, Testosterone cypionate 100 mg
- Where
- 10 sites in United States
- Volunteers
- 190 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Hypogonadism
NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)
The design of the study is a standard double-blind design, which is needed in this study to allow for unbiased evaluation of efficacy and safety.
- Trial name
- NCT01092858
- Testing
- Testosterone Undeconate (Nebido, BAY86-5037)
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Bayer
Secondary Hypogonadism
An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
To determine the safety profile of Androxal in men with secondary hypogonadism.
- Trial name
- NCT01739582
- Testing
- Androxal
- Volunteers
- 300 people
- Sponsor
- Repros Therapeutics Inc.
Male Hypogonadism
Safety and Efficacy Trial of Testosterone Undecanoate
The purpose of the study is to determine if oral testosterone undecanoate is effective and safe in the treatment of low testosterone in men.
- Trial name
- NCT01765179
- Testing
- Oral testosterone undecanoate
- Where
- 27 sites in United States
- Volunteers
- 144 people
- Sponsor
- Clarus Therapeutics, Inc.
Hypogonadism, Testosterone Deficiency
An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men
This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.
- Trial name
- NCT02082197
- Testing
- ABT-SLV176
- Where
- 42 sites in United States
- Sponsor
- AbbVie
Obese Hypogonadotropic Hypogonadism
Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men
This study is designed as a 2-part study, with Part 1 being open-label to best determine the appropriate dose levels to use in Part 2, which has a randomized, double-blind, placebo controlled design.
- Trial name
- OHH (NCT01200862)
- Testing
- Investigational new drug company code: BGS649
- Where
- 5 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Mereo BioPharma